Sartorius Stedim Biotech Confirms 2026 Outlook

• Sartorius Stedim Biotech confirmed FY 2026 Sartorius Group sales growth guidance of approximately 5%-9%, with an underlying EBITDA margin slightly above 30%.
• Bioprocess Solutions retained sales growth guidance of approximately 6%-10%, targeting an underlying EBITDA margin slightly above 32%.
• Lab Products & Services expects growth near the upper end of 2%-6%, with its margin outlook raised to slightly above 21%.
• The Group lowered its capital expenditure ratio forecast to approximately 12% from approximately 12.5%.
• Nine-month Group sales rose 4.9% to €2.74 billion; underlying EBITDA margin expanded 0.5 percentage points to 30.2%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sartorius Stedim Biotech SA published the original content used to generate this news brief on October 22, 2026, and is solely responsible for the information contained therein.